Alan Cantor, MD, PhD
Alan Cantor's laboratory is focused on further elucidating the transcriptional mechanisms that regulate normal hematopoiesis and how they may be perturbed in certain inherited platelet disorders and hematologic malignancies. They are also interested in understanding the mechanisms that regulate human developmental globin gene switching, and applying this to the treatment of beta-hemoglobinopathies such as sickle cell anemia and beta-thalassemia. Cantor and colleagues are specifically interested in the role of GATA, FOG, RUNX and ETS family transcription factors.
The Cantor laboratory is currently taking a number of approaches to these studies. This includes: (1) proteomic techniques to isolate and characterize multiprotein complexes involving these factors; (2) chromatin immunoprecipitation coupled to high throughput DNA sequencing (ChIP-seq) to identify sites occupied by these transcription factors across the genome; (3) gene targeting in mice; (4) ShRNA-mediated gene knock down experiments in primary human CD34+-derived cells; and (5) human genetic analysis of families with inherited thromboctyopenias and predisposition to leukemia.